A Single-Dose, Open-Label, Randomized, Three-Way Crossover Study of the Comparative Bioavailability of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets and of the Effect of Food on the Pharmacokinetics of TNX-102 in Healthy Adults.

Trial Profile

A Single-Dose, Open-Label, Randomized, Three-Way Crossover Study of the Comparative Bioavailability of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets and of the Effect of Food on the Pharmacokinetics of TNX-102 in Healthy Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2014

At a glance

  • Drugs Cyclobenzaprine (Primary)
  • Indications Fibromyalgia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Tonix Pharmaceuticals Inc
  • Most Recent Events

    • 14 Sep 2012 Planned End Date changed from 1 Jan 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 05 Apr 2012 Status changed from active, no longer recruiting to completed.
    • 09 Dec 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top